StocksMedium•1 October 2026•
1 min read
Monte Rosa Therapeutics Reports Positive Phase 1 Results for Heart Disease Drug MRT-8102
Key Facts
1Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, targeting inflammatory drivers of atherosclerotic cardiovascular disease (ASCVD).
2The drug demonstrated the ability to reduce inflammatory biomarkers to normal physiological levels with a favorable safety profile and no serious adverse events.
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, targeting inflammatory drivers of atherosclerotic cardiovascular disease (ASCVD). GlobeNewswire reported that the drug demonstrated the ability to reduce inflammatory biomarkers to normal physiological levels with a favorable safety profile and no serious adverse events.
The study focused on normalizing pathogenic drivers in subjects with elevated cardiovascular risk. GLUE closed at $11.93 on September 30, 2026, with the stock trading between a day low of $11.65 and a day high of $12.15 during that session.